Please login to the form below

Not currently logged in
Email:
Password:

FDA rules on children's cough medicines

The FDA has said that cough medicines should not be given to children aged under two years, unless approved by a doctor

The FDA has said that cough medicines should not be given to children aged under two years, unless approved by a doctor.

The ruling is the first major reassessment of the safety of children's cough and cold medicine for over ten years. Additional warnings about the drugs may materialise, because the FDA revealed it would be meeting with a panel of independent experts on 18 October.

It is anticipated that the experts will advise the agency about how new label warnings or prohibitions should be implemented. The panel will also discuss the ways in which parents and caregivers administer the drugs to children.

In high enough doses, cold medicines affect the beat of the heart and cause arrhythmia. Also, other types of cold and flu medicines constrict blood vessels. The medicines have been associated with high blood pressure, strokes and injury in cases where a child has been over-medicated.

The FDA has ruled that children should never be given cough and cold medicines which have been packaged for adults. The agency further advised that parents should closely follow label directions about the appropriate dose to give their children.

In March 2007, a group of paediatricians and public health officials petitioned the FDA to remove medicines intended for children under the age of six. The petition stated that the medicines did not work and could result in serious injury in rare cases.

The medicines under review include Toddler's Dimetapp, Infant Triaminic and Little Cold. Many of the active ingredients in these products have never undergone safety reviews by the FDA.

16th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...

Infographics